These results indicate not only that the observed estrogen dependence of Hec50 cell tumors is due to GPER but also that pharmacological inhibition of GPER could represent an important new therapy for women, particularly those with aggressive type II endometrial cancer. The gene discussed is GPER1; the disease is endometrial cancer.